Research Paper Volume 16, Issue 1 pp 550—567
Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study
Figure 4. Kaplan–Meier curves of progression-free survival (PFS) of elderly patients (age ≥65 years) treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). (A) All EGFR-TKIs; (B) gefitinib; (C) erlotinib; and (D) afatinib. Abbreviation: CI, confidence interval.